Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

By E. Van Cutsem, W. Vervenne, J. Bennouna, Y. Humblet, S. Gill, J. Van Laethem, C. Verslype, W. Scheithauer, A. Shang, J. Cosaert and 1 more. Journal of Clinical Oncology, 2009

647 citations recorded by the source corpus.

Subfields: Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/a9f2d5eea33bbdc554ca1e3fdc6b20748c685066

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Goldstein
2. D. Schrag
3. H. Kindler
4. S. Siena
5. J. Tabernero
6. D. Niedzwiecki
7. V. Heinemann
8. R. El-Maraghi

Citations in the corpus

• nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. (2015, background): “Median years (range), y 62 (27-86) 63 (32-88) 63 (27-88)”
• Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). (2010, result): “They are, however, similar to data from other randomized trials of the VEGF inhibtors bevacizumab, axitinib, and aflibercept in this disease.(22-24) Patient selection is likely the most important factor in the disparate results of this phase III CALGB study and the phase II trial that provided the s”